Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML
<br /> Farhad Ravandi-Kashani, MD, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia.
Farhad Ravandi-Kashani, MD, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia (AML).
According to Ravandi-Kashani, all patients with AML have expression of CD33, so it is almost a universally present target. In acute lymphoblastic leukemia, an anti-CD33 bi-specific T-cell engager (BiTE), such as blinatumomab (Blincyto), has been useful for the relapsed/refractory population, as well as in those with measurable minimal residual disease (MRD).
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More
